Precision Antibody-Based Synergistic Drug Combinations for Refractory Triple-Negative Breast Cancer
Abstract
Metastatic triple-negative breast cancer (mTNBC) represents an unmet clinical need. Our group recently led the clinical development of a new therapy for TNBC called sacituzumab govitecan (SG). Herein, we propose to capitalize on this treatment innovation. First is a laboratory based component that tests the mechanisms and effectiveness of specific drug combinations with SG, asking in part whether the combinations will work in multiple different TNBC models. Second is an animal-based component, in which we will test how effective the most promising combinations with SG are, how well-tolerated these combinations are, and whether staggered dosing schedules might preserve efficacy while minimizing side effects. Third is analysis of specimens from SG-treated patients, testing predicted biomarkers of response and resistance to SG, and using molecular analysis to discover new biomarkers. This analysis will highlight resistance mechanisms to SG and will help guide selection of TNBC patients who will benefit most from either single-agent SG or the new combinations.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 01, 2022
- Accession Number
- AD1169491
Entities
People
- Aditva Bardia
- Leif W Ellisen
Organizations
- Massachusetts General Hospital